Glenbriar Announces Access Codes for Annual Shareholder Meeting

Glenbriar Technologies Inc. (CSE:GTI.X) (the "Company") announces that due to the ongoing COVID-19 pandemic and provincial health orders limiting the number of persons in public gatherings, the Company determined not to hold an in person shareholders meeting. The Annual General and Special Meeting of Shareholders is being held through the Zoom application, which requires internet connectivity

In order to access the Meeting through Zoom, Shareholders will need to download the application onto their computer or smartphone and then once the application is loaded, enter the Meeting ID and Password below or open the following link:

Time: Apr 14, 2021 12:30 PM Pacific Time (US and Canada)

Join Zoom Meeting
https://us05web.zoom.us/j/87946580129?pwd=bkR4dXE5dDhXTEZiZTREUzhNNCthQT09

Meeting ID: 879 4658 0129
Passcode: iNaQ83

For further information, please contact:

Doug Taylor, CEO
Investor Relations
Telephone: 1 (778) 724-1301
E-mail: irglenbriartech@gmail.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this release may constitute "forward-looking statements" or forward looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE: Glenbriar Technologies Inc.



View source version on accesswire.com:
https://www.accesswire.com/640072/Glenbriar-Announces-Access-Codes-for-Annual-Shareholder-Meeting

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less

Latest Press Releases

Related News

×